使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to Baxter International's fourth-quarter 2016 earnings conference call.
歡迎參加百特國際(Baxter International)2016 年第四季財報電話會議。
(Operator Instructions)
(接線員指示)
As a reminder, this conference call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
提醒各位,本次電話會議由百特錄音,並屬受著作權保護之資料。未經百特許可,不得錄音或轉播。如有任何異議,請於此時中斷連線。現在我想將電話會議交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,您可以開始了。
- VP of IR
- VP of IR
Thanks, Candace. Good morning. Welcome to our fourth-quarter 2016 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer. On the call this morning, we will be discussing Baxter's fourth-quarter and full-year 2016 financial results, along with our outlook for 2017 before taking your questions.
謝謝你,Candace。各位早安。歡迎參加我們 2016 年第四季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。今天早上的電話會議中,我們將討論百特 2016 年第四季與全年財務結果,以及 2017 年展望,之後再回答各位的提問。
Please note that we have also posted a supplemental presentation to complement this morning's discussion. This presentation can be accessed on Baxter's external website in the Investor section, under Events & Presentations. In addition, I would like to remind you to please limit yourself to one question during the Q&A session, so we can accommodate others in the queue.
請注意,我們也已上傳一份補充簡報,以配合今天早上的討論。該簡報可於百特對外網站的「投資人」專區中,在「活動與簡報」項下取得。此外,也提醒各位在問答環節中請每人限問一題,以便讓隊列中的其他人也能提問。
With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product developments and regulatory matters, contain forward-looking statements that involve risks and uncertainties. And, of course, our actual results could differ materially from our current expectations.
接下來,我先以預備講稿開場,提醒各位本次簡報(包含關於我們財務展望、新產品開發與法規事項的評論)含有前瞻性陳述,並涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。
Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially. In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.
請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得可能導致實際結果與預期有重大差異之因素的更多細節。此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布的財報新聞稿中,並可於我們網站取得。
Now, I'd like to turn the call over to Joe.
現在,我想把電話會議交給 Joe。
- Chairman & CEO
- Chairman & CEO
Good morning, everyone. Thanks for joining us. I will start the day with some comments on our fourth-quarter performance and I will also share some perspective update on the year on how we'll deal with our momentum in 2017 and beyond. Jay will then take a closer look at our financials and outlook for 2017. I will close with the Q&A.
各位早安。感謝各位加入我們。我將先就第四季表現發表一些評論,也會分享對今年的最新觀點,說明我們將如何在 2017 年及之後延續動能。接著 Jay 會更深入檢視我們的財務狀況與 2017 年展望。最後我將進入問答環節。
As you saw in this morning's press release, Baxter finished the year with another strong quarter. We delivered fourth-quarter sales growth at 2% on both constant currency and reported basis. Adjusting for generic competition for cyclophosphamide in the US, sales increased 3% in the quarter. Key drivers include a strong performance in US fluid systems and anesthesia, along with continued momentum in peritoneal dialysis and acute renal care.
如各位在今早新聞稿中所見,百特以另一個強勁季度為今年畫下句點。我們第四季銷售成長在固定匯率與報告基礎上皆為 2%。若排除美國環磷醯胺(cyclophosphamide)面臨學名藥競爭的影響,該季銷售成長為 3%。主要驅動因素包括美國輸液系統與麻醉業務的強勁表現,以及腹膜透析與急性腎臟照護持續的動能。
Globally price contributed approximately 1 percentage point to growth in the quarter. On the bottom line, adjusted earnings were $0.57 per diluted share, an increase of more than 30% versus the prior year. Growth in the quarter reflects solid sales, improved gross margin and the benefit of our ongoing business transformation efforts.
在全球範圍內,價格因素約為本季成長貢獻 1 個百分點。在獲利方面,調整後每股稀釋盈餘為 0.57 美元,較去年同期增加逾 30%。本季成長反映了穩健的銷售、毛利率改善,以及我們持續推動業務轉型所帶來的效益。
Now I'll discuss performance by business and franchise on a constant currency basis to provide a clearer look at underlying operational performance. In the quarter, hospital product sales told $1.6 billion globally, increasing 1%. Adjusted for cyclophosphamide sales improved 2% globally in line with our expectations.
接下來我將以固定匯率基礎,按事業與產品線(franchise)說明表現,以更清楚呈現基礎營運表現。本季,醫院產品(Hospital Products)全球銷售額為 16 億美元,成長 1%。若調整環磷醯胺影響,全球銷售改善 2%,符合我們的預期。
Taking a closer look at fourth-quarter performance by franchise, our sales in fluid systems were $614 million, up 8%. Performance was driven by favorable pricing and deployment for IV solutions in the US along with incremental placements of the SIGMA SPECTRUM infusion system and the related pull through of access sets. Fluid systems sales growth in the quarter was negatively affected by 1 percentage point of the strategic access of IV solutions in selected markets outside the US.
進一步按產品線檢視第四季表現,我們的輸液系統(fluid systems)銷售額為 6.14 億美元,成長 8%。表現主要受惠於美國靜脈輸液(IV)解決方案的有利定價與鋪貨,以及 SIGMA SPECTRUM 輸注系統的新增裝機,並帶動相關輸注管路(access sets)的連帶銷售。本季輸液系統銷售成長受到影響:在美國以外部分選定市場對 IV 解決方案進行策略性供應(strategic access),使成長率減少 1 個百分點。
Integrated Pharmacy Solutions or IPS was for sale for $563 million, a 4% decline, adjusted for cyclophosphamide sales decreased 2%. Performance in the quarter was impacted by lower sales in nutrition globally given the increased competitive environment, lower pharmacy compounding sales and higher sales deductions.
整合藥局解決方案(Integrated Pharmacy Solutions,IPS)銷售額為 5.63 億美元,下滑 4%;若調整環磷醯胺影響,銷售下滑 2%。本季表現受到多項因素影響,包括在競爭加劇下全球營養產品銷售下滑、藥局調配(compounding)銷售降低,以及銷售扣減(sales deductions)增加。
Surgical Care sales of $349 million, up 1% in the quarter, mid single-digit growth in our anesthesia business offset by lower sales in biosurgery. While we were disappointed with the biosurgical performance, we continue to view this business as a core growth platform. We have significantly reallocated investments to biosurgery to improve performance.
外科照護(Surgical Care)銷售額為 3.49 億美元,本季成長 1%;麻醉業務達中個位數成長,抵銷了生物外科(biosurgery)銷售下滑。雖然我們對生物外科的表現感到失望,但我們仍將此業務視為核心成長平台。我們已大幅重新配置對生物外科的投資,以改善表現。
In addition, we're pleased to welcome Wil Boren to the new role of President, Biosurgery. Wil is a 20-year healthcare veteran with extensive global leadership in surgical care experience. We'll benefit from his experience and expertise as we expand our presence in this high potential market.
此外,我們也很高興歡迎 Wil Boren 出任新職務:生物外科總裁(President, Biosurgery)。Wil 擁有 20 年醫療保健產業資歷,並在外科照護領域具備豐富的全球領導經驗。隨著我們擴大在此高潛力市場的布局,我們將受益於他的經驗與專業。
Finally, in Hospital Products, fourth-quarter sales of $104 million in other declined 6% year-over-year reflecting lower manufacturing services revenues from Shire. Adjusted for those impacts, sales growth in the quarter was comparable to the prior year.
最後,在醫院產品中,「其他」第四季銷售額為 1.04 億美元,年減 6%,反映來自 Shire 的製造服務收入較低。若調整上述影響,本季銷售成長與去年同期相當。
Moving on to the renal business, global renal sales for Q4 were $1 billion, reflecting 5% growth. We continue to see strong momentum, rather, in peritoneal dialysis with growth of 7% globally, driven by patient growth of 6% along with favorable pricing and product mix in the US where we now have nearly 1,500 patients on AMIA. Fourth-quarter renal results also benefited from our high single-digit growth in acute renal care. Our PRISMAFLEX system continues to lead the rapidly growing market for continuous renal replacement therapy or CRRT.
接著談腎臟事業,第四季全球腎臟業務銷售額為 10 億美元,成長 5%。我們持續看到腹膜透析的強勁動能,全球成長 7%,主要由病患數成長 6%所帶動,並受惠於美國有利的定價與產品組合;目前我們已有近 1,500 名病患使用 AMIA。第四季腎臟業務結果亦受惠於我們在急性腎臟照護(acute renal care)達到高個位數成長。我們的 PRISMAFLEX 系統持續領先快速成長的連續性腎臟替代治療(continuous renal replacement therapy,CRRT)市場。
In-center hemodialysis performance declined slightly in the quarter, but we were pleased to see growth stabilizing following a number of actions we have taken increasing its performance. Growth improved 2 percentage points sequentially. Importantly, profitability continues to improve in this business. In the fourth quarter, we launched our novel and proprietary HDx therapy enabled by our THERANOVA dialyzer, which has the potential to raise the standard of treatment and improve outcomes for end stage renal disease patients.
本季院內血液透析(in-center hemodialysis)表現略為下滑,但我們很高興看到在採取多項提升表現的措施後,成長已趨於穩定。成長率較前一季改善 2 個百分點。更重要的是,該業務的獲利能力持續改善。第四季我們推出由 THERANOVA 透析器所支援的創新且專有的 HDx 治療,具備提升治療標準並改善末期腎臟病患者預後的潛力。
With that, let's shift focus to the full year. This call marks my first anniversary as Baxter's CEO. I found that at a Company with a solid foundation and good people, the goal quite simply has been to convert this potential to consistent top-quartile performance, to do it fast and do it well. Our full-year results demonstrate our progress towards this objective, mid single-digit growth, adjusted income of $1.96 per diluted share, and free cash flow greater than $900 million.
接下來,讓我們把焦點轉向全年表現。這通電話會議也標誌著我擔任百特執行長滿一週年。我發現,對一家擁有穩固基礎與優秀人才的公司而言,目標其實很簡單:把這些潛力轉化為穩定的前四分位(top-quartile)表現,而且要做得快、做得好。我們的全年結果展現了朝此目標邁進的進展:中個位數成長、調整後每股稀釋盈餘 1.96 美元,以及超過 9 億美元的自由現金流。
Our business transformation has focused on three clearly defining strategic levers, portfolio and innovation management, operational excellence, and capital allocation. We rolled out this strategy at our 2016 Baxter conference along with our Baxter 2020 financial targets. It has been about execution since then. This passion for portfolio management has meant taking a hard look at where we drive the greatest value for patients and the business across our vast portfolio and global footprint and then investment according to the strengthened top-line growth and ROIC.
我們的業務轉型聚焦於三個明確界定的策略槓桿:產品組合與創新管理、營運卓越,以及資本配置。我們在 2016 年百特大會上推出此策略,並同時公布 Baxter 2020 財務目標。自那之後,重點一直在於執行。這份對產品組合管理的熱忱,意味著我們必須嚴格檢視在龐大的產品組合與全球布局中,哪些領域能為病患與公司創造最大價值,並依據強化的營收成長與投資資本報酬率(ROIC)進行投資。
We have made some very candid assessments that have been crucial to optimize our portfolio, go to market strategy and commercial mindset. Some of these decisions will impact our top line growth in 2017, but position Baxter for accelerated growth as we redirect resources to higher growth, higher margin opportunities.
我們已做出一些非常坦率的評估,這些評估對於優化我們的產品組合、上市策略與商業思維至關重要。其中部分決策將影響我們2017年的營收成長,但在我們將資源重新導向至更高成長、較高毛利的機會之際,將使百特得以加速成長。
Just like our portfolio, our research and development pipeline must drive clear value for the patients and the business. In 2016, we accelerated R&D productivity and shifted differential investment to our core growth areas and compelling strategic bets. These actions will create a foundation for ongoing growth.
正如我們的產品組合一樣,我們的研發管線必須為病患與企業帶來明確價值。2016年,我們加速提升研發生產力,並將差異化投資轉向我們的核心成長領域與具吸引力的策略性押注。這些行動將為持續成長奠定基礎。
We have also made excellent progress establishing a more efficient organizationally structured and disciplined cost management strategies. While these actions have meaningful -- have rather meaningfully contributed margin expansion in 2016, we'll continue to identify new initiatives through our business transformation office to drive operational efficiency across our organization.
我們在建立更高效率的組織架構與更具紀律的成本管理策略方面也取得了極佳進展。儘管這些行動在2016年對毛利率擴張做出了顯著貢獻,我們仍將透過業務轉型辦公室持續辨識新的倡議,以推動全組織的營運效率。
Executing our capital allocation strategy ensures appropriate investment in our business and return of credit to shareholders is pivotal to deliver sustained top-quartile performance. In 2016, we successfully completed disposition of the Baxalta retained stake and have optimistically restructured debt, among the steps to fuel growth and create value. Reward to shareholders is essential to this equation, which we emphasized through a 13% dividend increase and opportunistic share repurchases of approximately $300 million.
執行我們的資本配置策略,確保對業務進行適當投資並向股東回饋資本,是實現持續名列前茅績效的關鍵。2016年,我們成功完成處分保留的Baxalta持股,並以更有利的條件重整債務等多項措施,以推動成長並創造價值。對股東的回饋是此方程式中不可或缺的一環;我們透過將股利提高13%以及把握時機回購約3億美元股份來強調這一點。
Finally, we initiated the acquisition of Claris Injectables to provide a key platform for future growth. So in sum, it has been a year of rapid and meaningful strategic execution across the board in advancing both the top line and bottom line.
最後,我們啟動對Claris Injectables的收購,以提供未來成長的關鍵平台。總而言之,這一年我們在推進營收與獲利兩端方面,全面快速且具實質意義地執行了策略。
Am I satisfied? No, but we are off to a solid start. There's more to come. With that, I will turn it over to Jay.
我滿意嗎?不,但我們已經有一個穩健的開端。後續還有更多。接下來我把時間交給Jay。
- CFO
- CFO
Thanks, Joe. Good morning, everyone. As Joe mentioned, we're pleased with our fourth-quarter results demonstrating continued progress towards achieving our long-term financial goals. Sales in the quarter increased 2% on both a reported basis and constant currency basis, in line with our expectation. Walking through the rest of the P&L, adjusted gross margin of 44.5%, represented an improvement of nearly 200 basis points over the prior year, driven by improved pricing in select areas of the portfolio and favorable manufacturing performance in the quarter.
謝謝,Joe。各位早安。如Joe所提到的,我們對第四季的業績感到滿意,顯示我們持續朝長期財務目標邁進。本季銷售額在報表基礎與固定匯率基礎下皆成長2%,符合我們的預期。接著看損益表其餘項目,調整後毛利率為44.5%,較去年同期提升近200個基點,主要受惠於產品組合中部分領域的定價改善,以及本季製造表現有利。
Adjusted SG&A totaled $619 million, decreasing 8% on a reported basis. The primary driver of the improvement was our ongoing focus on controlling expenses and the benefit from lower pension expenses. TSA income totaled approximately $23 million in the quarter, compared to approximately $30 million in the fourth quarter of 2015. As mentioned last quarter, TSA income from Shire will continue to decline as the need for these services ramps down, which is expected to be by mid 2017.
調整後銷售、一般及行政費用(SG&A)合計為6.19億美元,按報表基礎下降8%。改善的主要驅動因素是我們持續專注於費用控管,以及較低的退休金費用所帶來的效益。本季TSA收入約為2,300萬美元,較2015年第四季約3,000萬美元下降。如上季所提,來自Shire的TSA收入將隨著對這些服務的需求逐步降低而持續下滑,預計至2017年年中。
Adjusted R&D spending in the quarter of $152 million decreased 4% versus the prior year. Adjusted operating margin in the quarter was 15.4%, an improvement of 470 basis points versus prior year. Operating margin compared favorably to our expectations driven by improved gross margin and disciplined expense management. Interest expense was $13 million in the fourth quarter.
本季調整後研發(R&D)支出為1.52億美元,較去年同期下降4%。本季調整後營業利益率為15.4%,較去年同期提升470個基點。營業利益率優於我們的預期,主要受惠於毛利率改善與嚴謹的費用管理。第四季利息費用為1,300萬美元。
Adjusted other income totaled $19 million in the quarter, primarily resulting from gains on the sale of select investments and a foreign exchange benefit on balance sheet positions. The adjusted tax rate was 24.5% for the quarter. This rate was higher than expected and reflects the finalization of the effective tax rate for the full year, which reflects incremental profitability generated in higher tax jurisdictions in 2016 as compared to 2015.
本季調整後其他收益合計為1,900萬美元,主要來自出售部分投資的收益,以及資產負債表部位的外匯收益。本季調整後有效稅率為24.5%。該稅率高於預期,反映我們完成全年有效稅率的最終確認;與2015年相比,2016年在較高稅負司法管轄區所產生的增量獲利較多。
As previously mentioned, adjusted earnings was $0.57 per diluted share, exceeded our guidance of $0.49 to $0.52 per share. Relative to the midpoint of our range, this favorability was driven by approximately $0.06 of operational strength and a $0.02 benefit from other income. This was partially offset by approximately $0.02 due to a higher tax rate.
如先前所述,調整後每股盈餘為稀釋後每股0.57美元,超出我們每股0.49至0.52美元的指引。相較於區間中點,優於預期主要來自約0.06美元的營運強勁表現,以及其他收益帶來約0.02美元的貢獻。部分被較高稅率造成約0.02美元的不利影響所抵銷。
During the fourth quarter, we opportunistically repurchased approximately $250 million, or approximately 5 million shares during the quarter. These repurchases were partially offset by option related dilution. Before I turn to our outlook for 2017, I wanted to spend some time discussing our cash flow performance.
第四季期間,我們把握時機回購約2.5億美元、約500萬股的股份。這些回購部分被與選擇權相關的稀釋所抵銷。在我談2017年展望之前,我想先花一些時間討論我們的現金流表現。
In 2016, we generated free cash flow of $905 million, an improvement of more than $550 million versus 2015 and ahead of our most recent guidance of $650 million for 2016. This improvement was driven by strong operational performance, disciplined management of capital expenditures which declined by nearly $200 million, along with the implementation of new programs focused on improving the Company's working capital.
2016年,我們產生自由現金流9.05億美元,較2015年改善超過5.5億美元,並高於我們最近對2016年6.5億美元的指引。此改善來自強勁的營運表現、對資本支出(CapEx)的嚴謹管理(資本支出下降近2億美元),以及導入聚焦於改善公司營運資金的新方案。
These new initiatives around days payable and days receivable contributed to the strong cash generation in the fourth quarter. We also took the opportunity in the quarter to repatriate approximately $1 billion in overseas cash to the US. We were able to bring this cash back to the US in a tax efficient manner, via the partial repayment of an intercompany loan as well as repatriation of previously taxed earnings in certain foreign jurisdictions.
這些針對應付天數與應收天數的新倡議,促成第四季強勁的現金創造。我們也在本季把握機會,將約10億美元的海外現金匯回美國。我們透過部分償還公司間貸款,以及在特定海外司法管轄區匯回先前已課稅的盈餘,以具稅務效率的方式將這筆現金帶回美國。
Let me conclude my comments this morning by providing an update on our outlook for 2017. Starting with sales, on a constant currency basis, we expect 2017 full-year sales for Baxter to increase approximately 2%. After adjusting for the US cyclo impact and the select strategic product exits we've discussed, we expect underlying operational growth of approximately 4%. This growth is in line with our long-term projections and does not reflect any benefit from the proposed Claris acquisition.
最後,讓我在今天早上的發言以更新我們對2017年的展望作結。先從銷售額談起,以固定匯率基礎計算,我們預期百特2017年全年銷售額約成長2%。在調整美國cyclo影響以及我們已討論的部分策略性產品退出後,我們預期基礎營運成長約為4%。此成長與我們的長期預測一致,且未反映擬議中的Claris收購所帶來的任何效益。
With respect to Claris, we expect the acquisition to close in the second half of 2017. We'll provide updated expectations following completion of the acquisition. On a reported basis, including the impact of foreign exchange, we expect full-year 2017 sales to be comparable to the prior year. We expect growth in the Hospital Products business of 1% to 2% or approximately 3% to 4% excluding cyclo and strategic exits.
就Claris而言,我們預期該收購將於2017年下半年完成交割。在收購完成後,我們將提供更新的預期。以報表基礎計算(包含外匯影響),我們預期2017年全年銷售額將與前一年大致相當。我們預期醫院產品(Hospital Products)業務成長1%至2%;若排除cyclo與策略性退出,約成長3%至4%。
Within the Hospital Products franchise, we expect sales growth of 2% to 3% for Fluid Systems. Adjusting for strategic exits, we expect growth of 4% to 5%. For the Integrated Pharmacy Solutions franchise, we expect sales to decline low single-digits. We expect full-year sales for cyclo of $115 million as compared to $210 million in 2016. Our assumption is that additional competitors enter the market during the second and third quarters of 2017. After adjusting for cyclo, sales are expected to increase 3% in IPS.
在醫院產品事業群中,我們預期輸液系統(Fluid Systems)銷售成長2%至3%。若調整策略性退出,我們預期成長4%至5%。對於整合藥局解決方案(Integrated Pharmacy Solutions, IPS)事業群,我們預期銷售將小幅下滑(低個位數)。我們預期cyclo全年銷售額為1.15億美元,相較2016年的2.10億美元。我們的假設是,2017年第二與第三季將有更多競爭者進入市場。在調整cyclo後,IPS銷售預期將成長3%。
Within the surgical care franchise, we anticipate sales to grow approximately 2% to 3%. Both the anesthesia and biosurgery businesses are expected to grow in that range. Finally, for the Hospital Products business, we now expect BPS and other to increase low to mid single-digits.
在外科照護(surgical care)事業群中,我們預期銷售約成長2%至3%。麻醉(anesthesia)與生物外科(biosurgery)業務預期皆將在該區間內成長。最後,就醫院產品業務而言,我們目前預期BPS及其他項目將以低至中個位數成長。
In the renal business, we expect full-year sales to increase 3% to 4%, driven by continued growth across the segment. Adjusting for select strategic exits, sales are expected to increase between 4% to 5%.
在腎臟(renal)業務方面,我們預期全年銷售額成長3%至4%,主要由該部門持續的全面成長所帶動。若調整部分策略性退出,銷售額預期將成長4%至5%。
Moving down the P&L, we expect an operating margin of 15%, approximately 150 basis points improvement versus 2016. This is ahead of our long-term outlook we provided in May 2016 and reflects the benefit of all of the actions we've taken to optimize our cost structure. We expect to provide an update for long-term guidance on our second-quarter conference call.
沿著損益表往下看,我們預期營業利益率為15%,較2016年約提升150個基點。這高於我們在2016年5月提供的長期展望,並反映我們為優化成本結構所採取各項行動帶來的效益。我們預期將在第二季法說會上更新長期指引。
We expect interest expense to total approximately $60 million and other income of approximately $20 million for 2016. For the year, we expect an average adjusted tax rate of approximately 20.5%. This reflects a benefit of $20 million, or approximately $0.03, related to the adoption of the new stock compensation guidance. For full year 2017, we anticipate an average share count of 550 million shares. Based on these factors, we expect 2017 adjusted earnings, excluding special items, of $2.10 to $2.18 per diluted share.
我們預期2016年利息費用合計約6,000萬美元,其他收益約2,000萬美元。全年而言,我們預期平均調整後有效稅率約為20.5%。這反映採用新的股票薪酬會計指引所帶來的2,000萬美元利益,約合每股0.03美元。就2017全年而言,我們預期平均流通股數為5.5億股。基於上述因素,我們預期2017年調整後盈餘(不含特殊項目)為每股稀釋後2.10至2.18美元。
Finally for the year, we expect to generate operating cash flow of approximately $1.75 billion and free cash flow of approximately $1 billion. Specific to the first quarter of 2017, we expect sales growth to increase approximately 2% to 3% on a reported basis and 3% to 4% on a constant currency basis. Adjusting for the impact of cyclo and selected strategic product exits, we expect underlying constant currency sales growth of 5% to 6%. We expect adjusted earnings, excluding special items, of $0.50 to $0.52 per diluted share.
最後,就全年而言,我們預期可產生約17.5億美元的營運現金流,以及約10億美元的自由現金流。針對2017年第一季,我們預期以報告基礎計算的銷售成長約增加2%至3%,以固定匯率基礎計算約增加3%至4%。若調整cyclo的影響以及部分策略性產品退出,我們預期基礎固定匯率銷售成長為5%至6%。我們預期調整後盈餘(不含特殊項目)為每股稀釋後0.50至0.52美元。
With that, we can now open up the call for Q&A.
接下來,我們現在開放問答。
Operator
Operator
(Operator Instructions)
(接線員指示)
I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter international website for 60 days at www.Baxter.com.
提醒各位與會者,本次電話會議將被錄音,並將在Baxter International網站www.Baxter.com提供為期60天的數位重播。
Mike Weinstein, JPMorgan.
JPMorgan的Mike Weinstein。
- Analyst
- Analyst
First off, congratulations on another fine quarter. Let me ask you a couple questions on the guidance if I can, Jay. So your 20 -- well, let me step back. Your margins over the last two quarters have obviously been exceptional. You've made a ton of progress. Your EBITDA margin was 15.4% this quarter, 16% last quarter. Your 2017 guidance is for 15%. So tell me, why is 15% the right number for 2017 given the second half of 2016 performance?
首先,恭喜你們又交出一個很好的季度成績。Jay,如果可以的話,我想就指引問你幾個問題。所以你們的20——嗯,讓我先退一步說。你們過去兩個季度的利潤率顯然非常出色。你們取得了很大的進展。你們本季EBITDA利潤率為15.4%,上季為16%。你們對2017年的指引是15%。那麼,考量2016年下半年的表現,為什麼15%會是2017年正確的數字?
- CFO
- CFO
Great. First of all, normal seasonality, we typically do better from a margin standpoint in the second half of the year versus the first half of the year. So there are a number of factors that drive that in terms of seasonality of sales and normal hospital buying patterns. But we do see some normal historic uptick in the second half of the year margins relative to the first half. That was certainly the case in 2016.
好的。首先,正常的季節性因素,我們通常在一年下半年、相較上半年,在利潤率方面表現更好。這背後有多項因素,包含銷售的季節性以及醫院正常的採購模式。但我們確實看到歷史上通常在下半年利潤率相對上半年會有正常的上升。2016年確實也是如此。
But interesting -- maybe I'll make a few comments in terms of overall guidance as we think about 2017 operating margin. Really, there's a number of factors at play. One of them is we do have a cyclo headwind moving into next year, right? So that's about 80 basis points of impact on operating margin or, call it, $0.13 of headwinds. From a foreign exchange standpoint, we have another roughly 30 basis points of headwind.
不過有趣的是——也許我會就我們看待2017年營業利益率的整體指引做幾點說明。其實有多個因素同時在發揮作用。其中之一是,我們在明年將面臨cyclo的不利因素,對吧?這對營業利益率的影響約為80個基點,或可說是0.13美元的不利影響。從外匯角度來看,我們還有約30個基點的不利影響。
From a TSA standpoint, we have about 50 basis points of headwind. So when you sum these up, we're talking about headwinds of roughly 150 basis points or actually as we calculate it another way, maybe $0.35 of headwinds. Now, converting that to performance, we expect to see adjusting for that roughly 300 basis points of margin improvement gross over those headwinds that takes us from on a full-year basis what was 13.6% to roughly 15% for 2017.
從TSA角度來看,我們約有50個基點的不利影響。因此把這些加總起來,我們談的是約150個基點的不利因素;或者用我們另一種計算方式,大約是0.35美元的不利影響。現在,把這轉換成營運表現來看,我們預期在扣除這些因素後,仍可在這些逆風之上實現約300個基點的毛利潤率改善,讓我們在全年基礎上從13.6%提升到2017年的約15%。
So there are a couple of factors that mask the quantum of the overall margin improvement. If you think about it from an overall EPS standpoint, like we said, we have about $0.35 of headwinds. We're doing a lot of work on the SG&A line. We're going to see normal operational growth and portfolio optimization that contribute that allows us to offset that. But it is a fairly substantial increase.
所以有幾個因素會掩蓋整體利潤率改善的幅度。如果從整體EPS角度來看,如我們所說,我們約有0.35美元的不利因素。我們在SG&A費用線上做了大量工作。我們將看到正常的營運成長與產品組合優化所帶來的貢獻,使我們能夠抵消這些影響。但這仍是一個相當可觀的提升。
- Analyst
- Analyst
Okay. Jay, just two follow-ups. So if I look back at the analyst meeting in June, your 2018 margin guidance was 14% to 15%. Your cash flow guidance was for $1.8 billion operating cash flow, $1 billion of free cash flow. You're going to hit those targets, if not exceed them in 2017. So the question is, are the 2018 targets that you laid out last June now basically no longer effective or operational? Then the second question is, are you assuming any share buybacks in your guidance for 2017? Thanks.
好的。Jay,我再追問兩點。如果我回頭看6月的分析師會議,你們對2018年的利潤率指引是14%到15%。你們的現金流指引是18億美元的營運現金流、10億美元的自由現金流。你們在2017年就會達到這些目標,甚至可能超過。所以問題是,你們去年6月提出的2018目標,現在基本上是否已不再適用或不再具有操作性?第二個問題是,你們在2017年的指引中是否假設有任何庫藏股回購?謝謝。
- CFO
- CFO
Yes. So as we think about the projections that we shared in May, I mean, I will tell you on the operating margin side and certainly on the free cash flow side, we're extremely pleased with the performance. So much so that we've pulled forward 2018 basically one year to 2017 from a margin standpoint, from a free cash flow standpoint. So we have to update those numbers.
是的。當我們思考5月分享的預測時,我可以告訴你,在營業利益率方面,當然也包括自由現金流方面,我們對表現非常滿意。滿意到我們基本上把2018年的成果從利潤率與自由現金流角度提前一年拉到2017年。因此我們必須更新這些數字。
My full expectation is we will be able to overachieve those numbers clearly based on the 2017 performance. But from an overall process standpoint, we go through a bottoms-up long range financial planning process. Our teams have initiated that work. It's work that we'll conduct over the next several months. We'll review the output with our Board of Directors.
我完全預期,基於2017年的表現,我們將能夠明顯超越那些數字。但就整體流程而言,我們會進行自下而上的長期財務規劃流程。我們的團隊已啟動這項工作。這項工作將在接下來幾個月內進行。我們會與董事會審視其產出。
Then I certainly look forward to sharing it with our investors at the July earnings call, in part because I do believe that there will be upside to the numbers that we've shared. As it relates to share buyback, we are assuming share buyback to offset dilution, so there is a few hundred million dollars of buyback embedded in our guidance.
接著我也非常期待在7月的財報電話會議上與投資人分享,部分原因是我確實相信,我們先前分享的數字會有上行空間。至於股票回購,我們假設會透過回購來抵消稀釋,因此我們的指引中已內含數億美元的回購。
As we've said, our standard approach, we don't commit to specific amounts, a lot of it depends on the evolution of the share price relative to the intrinsic value of our Company. In the fourth quarter, we saw a great opportunity because from an intrinsic value standpoint, the shares traded at higher discount than normal so we repurchased $250 million in shares. We'll look to do that again to the extent the opportunity presents itself in 2017. But from a planning standpoint, we basically have share buyback offsetting dilution.
如同我們所說,我們的標準作法是不承諾特定金額,其中很大一部分取決於股價相對於公司內在價值的變化。在第四季,我們看到一個很好的機會,因為從內在價值角度來看,股價以高於正常水準的折價交易,因此我們回購了2.5億美元的股票。若2017年出現同樣的機會,我們也會再度採取行動。但從規劃角度來看,我們基本上是以股票回購來抵消稀釋。
- Analyst
- Analyst
Perfect. Thank you, Jay.
完美。謝謝你,Jay。
- CFO
- CFO
Thank you.
謝謝。
Operator
Operator
Matt Taylor, Barclays.
Barclays的Matt Taylor。
- Analyst
- Analyst
So just a follow-up on the margin piece. You outlined a number of the headwinds. I would love to understand the components of margin expansion, if you could just kind of walk us through portfolio management, new products, cost savings, things like that so that we can understand the bridge that allows you to make such a nice jump over some of these hurdles in 2017.
我想就利潤率部分再追問一下。你提到了多項逆風因素。我很希望能了解利潤率擴張的組成,如果可以的話,請你大致帶我們走一遍,例如產品組合管理、新產品、成本節省等,讓我們能理解在2017年你們如何跨越其中一些障礙、實現如此漂亮的躍升。
- CFO
- CFO
No, it's a great question. I did focus on the headwinds in the first answer. As I said, we have about $0.35 worth of headwinds or 150 basis points. But the work that we're doing and the number of areas has paid remarkable dividends in 2016. We expect very big impacts in 2017.
不,這是個很好的問題。我在第一個回答中確實著重談到了逆風。如我所說,我們大約有 0.35 美元的逆風,或 150 個基點。但我們正在做的工作以及涵蓋的多個領域,在 2016 年帶來了顯著的成果。我們預期在 2017 年會有非常大的影響。
The area that I'll point out, from an SG&A standpoint, we expect about 120 basis points, 130 basis points of net improvement or roughly $0.18 related to the cost savings initiatives that we've put in place. Now, we have talked a lot about this concept of zero base budgeting and how from an organization standpoint and from a spending standpoint we've been incredibly disciplined on looking at every dollar consumed by our Company.
我想指出的一個領域是,從 SG&A 的角度來看,我們預期約有 120 個基點、130 個基點的淨改善,或約 0.18 美元,這與我們已推行的成本節省措施有關。我們已經談了很多零基預算(zero base budgeting)這個概念,以及從組織與支出角度來看,我們在檢視公司每一筆花費上一直非常自律。
That featured prominently in our results in 2016, but what it allows us to do in 2017 is improve our SG&A once again by 120, 130 basis points and $0.18. That's net of inflationary increases that we normally see from a payroll standpoint. So that one factor is a very big impact. Frankly, it offsets a number of the headwinds that we're facing. But then the next piece relates to normal operational growth.
這在我們 2016 年的業績中占了很重要的比重,而它讓我們在 2017 年能再次將 SG&A 改善 120、130 個基點以及 0.18 美元。這是在扣除我們通常在人事薪酬方面會看到的通膨性增加之後的淨額。因此,這一項因素的影響非常大。坦白說,它抵消了我們面臨的若干逆風。接下來的一部分則與正常的營運成長有關。
If you think about the normal operational growth that we've talked about, roughly 4% plus, that will contribute because we've walked away from sales that are zero margin really, that drops through at a higher level than the standard corporate average. When we start to see growth in those core growth areas, which attached to them have a higher margin than the corporate average, it has a great impact on the operating margin.
如果你想想我們談到的正常營運成長,大約 4% 以上,這會帶來貢獻,因為我們已經放棄了那些幾乎是零毛利的銷售,因此其落到利潤端的比率會高於標準的公司平均。當我們開始在那些核心成長領域看到成長,而這些領域的毛利率高於公司平均時,對營業利益率會有很大的影響。
So the operational growth of our business is roughly 170 basis points of positive impact. We'll see roughly north of $0.30 of benefit from those -- from the operational growth of Baxter. So taking a step back, we have a number of headwinds that we're fighting through, but we have two very important tailwinds. One is this SG&A focus that we have as an entire organization. Two is the drive to accelerate the growth of the business and the natural improvement that drives towards the bottom line.
因此,我們業務的營運成長大約帶來 170 個基點的正面影響。我們將從這些——也就是 Baxter 的營運成長——中看到大約超過 0.30 美元的效益。所以退一步看,我們確實有一些逆風需要克服,但我們也有兩個非常重要的順風。第一個是我們作為整個組織對 SG&A 的聚焦。第二個是推動加速業務成長,以及由此自然帶動的、對最終獲利的改善。
- Analyst
- Analyst
Great. Then just one follow-up. I would love to hear your updated thoughts on the Claris acquisition and the injectable space in general. Can you talk about how that is core to your strategy? Does Claris get you where you need to be in injectables? Are there other assets that you could add there? Or are other white spaces, kind of higher priority?
很好。那再追問一個問題。我很想聽聽你們對 Claris 收購案以及整體注射劑領域的最新看法。你能談談這如何成為你們策略的核心嗎?Claris 是否讓你們在注射劑方面達到所需的布局?那裡是否還有其他資產可以再加進來?或者是否有其他空白領域(white spaces)其優先順序更高?
- Chairman & CEO
- Chairman & CEO
Matt, the strategy we outlined is very clear. We're going to be into the injectable, difficult to make market. Claris is a step in the right direction. Between Claris and Baxter portfolio in the next three to five years, we'll be launching 100 different new molecules for us into the market.
Matt,我們所闡述的策略非常清楚。我們將進入注射劑、且是難以製造的市場。Claris 是朝正確方向邁出的一步。在未來三到五年內,結合 Claris 與 Baxter 的產品組合,我們將向市場推出 100 種不同的新分子。
We also have plans to sign several different collaborations and partnership agreements coming up. Probably in the next 30 days, we're going to probably have one or two. We're planning to have 100 more molecules on top of that. So expect more to come. We also have segregated our organization within Baxter to make sure that we have the right people in place to create the three competitive advantages that this market requires, which is cost, quality and speed.
我們也計畫簽署數個不同的合作與夥伴協議。大概在接下來 30 天內,我們可能會有一到兩個。在此之上,我們還計畫再增加 100 個分子。所以請期待後續還會有更多進展。我們也在 Baxter 內部將組織做了區隔,以確保配置正確的人才,打造這個市場所需要的三項競爭優勢:成本、品質與速度。
- Analyst
- Analyst
Great. Thank you very much.
很好。非常感謝。
Operator
Operator
Vijay Kumar, Evercore.
Vijay Kumar,Evercore。
- Analyst
- Analyst
Congratulations on another impressive performance here. Maybe I'll start with one in a high level to pick a question on the revenue guidance. Jay, if you look at a 2% constant revenue growth, I think there's been some question about what is the true underlying growth for Baxter ex-pricing. Can you just comment on volume versus price dynamic for the 2%?
恭喜你們再次交出令人印象深刻的表現。我先從較高層次的問題開始,想問一下營收指引。Jay,如果看 2% 的固定匯率營收成長,我想市場一直有些疑問:在不含定價因素下,Baxter 真正的內生成長是多少。你能否就這個 2% 的量與價的動態做些評論?
- CFO
- CFO
Yes. I mean, the 2% is principally volume related. There is a small impact of price included in that. By and large, it's a volume related number. We historically talked about this notion of organic or long-term sustainable growth of 4% with our expectations that we look to accelerate beyond that over time. But so as we sit here today, the 4% when you adjust for cyclo and the strategic exit, we're kind of broadly consistent with that.
可以。我的意思是,這 2% 主要是由銷量帶動。其中也包含一小部分的價格影響。整體而言,這是一個以銷量為主的數字。我們過去一直談到所謂有機、或長期可持續的 4% 成長概念,並期望隨時間推進能加速超越這個水準。但就我們今天的情況而言,當你把 cyclo 以及策略性退出的影響調整掉後,我們大致上與這個 4% 是一致的。
- Analyst
- Analyst
Great. Maybe one for Joe. Joe, when you think about the top cash rate, it really is a remarkable rate. You guys, last year, set out the target of $500 million, almost double the free cash. One, why is that $1 billion free cash for 2017 the right number? Were there any timing related impacts in the 2016 -- in the fourth-quarter period which sort of affects the comp? Two, what's the use of cash? If I do the math, 5 million shares repurchased for $250 million, that gets an average share price of $47.50. Your stocks right now are top, close to those levels. How should we think about M&A versus share repo? Thank you.
很好。也許問 Joe 一個問題。Joe,當你想到這個現金轉換率(cash rate),確實是非常驚人的水準。你們去年提出 5 億美元的目標,幾乎是自由現金流的兩倍。第一,為什麼 2017 年 10 億美元的自由現金流是合理的數字?2016 年——第四季期間是否有任何與時點相關的影響,進而影響同比比較?第二,現金的用途是什麼?如果我算一下,回購 500 萬股花了 2.5 億美元,平均股價約 47.50 美元。你們的股價現在也差不多在那些水準附近。我們應該如何看待併購(M&A)與股票回購之間的取捨?謝謝。
- CFO
- CFO
Yes, sure, let me talk about cash flow performance in 2016 and the guidance for 2017. I'll turn it over to Joe to talk about uses in M&A versus share buybacks. But I will tell you one of the areas -- there's a lot of things that went very well that we're very pleased with in 2016. But one of the areas that was really a bright, shining star was free cash flow performance. We did significantly overachieve the guidance that we shared in Q3.
好的,當然,我先談談 2016 年的現金流表現以及 2017 年的指引。至於 M&A 與股票回購的資金用途,我再交給 Joe 來說明。不過我可以告訴你,有一個領域——2016 年有很多事情進展得非常順利,我們也非常滿意。但其中真正的一顆明亮之星,是自由現金流的表現。我們明顯超越了在第三季所分享的指引。
Inherently, as we think about cash flow, it is difficult to forecast cash flow for a couple reasons. One is a lot of cash flow is typically generated at the very end of the year. Then the second point is because we have such large working capital balances today and because free cash flow has historically been such a small number, small improvements in working capital balance have a very leveraged effect on free cash flow. We clearly saw that play out.
本質上,當我們思考現金流時,現金流之所以難以預測有幾個原因。第一,很多現金流通常是在年底最後階段才產生。第二點是,因為我們目前的營運資金餘額非常大,而且歷史上自由現金流一直是很小的數字,所以營運資金餘額的小幅改善,會對自由現金流產生高度槓桿的效果。我們很清楚看到這一點的展現。
But I'll tell you, we were thrilled with the progress. From a working capital standpoint, we really pursued the transformation on three areas, right? Days payable, days sales outstanding and days inventory on hand. In every single area, our Baxter teams exceeded our expectations. So from a day sales outstanding, we're down two days year-over-year.
但我可以告訴你,我們對這項進展感到非常振奮。從營運資金的角度來看,我們主要在三個領域推動轉型,對吧?應付帳款天數、應收帳款週轉天數(DSO)以及存貨在手天數。在每一個領域,我們的 Baxter 團隊都超出我們的預期。以應收帳款週轉天數來看,我們年對年下降了兩天。
We have several countries that have historic decade low DSO. So the team in Spain has done just an extraordinary job. Our DSO in Spain is 100 days. I went to Europe in 2007, I haven't seen a DSO at that level in ages. Really the focus of the DSO effort was we did not want the Baxter team to stand in the way of a collection, right? We did not want to be a bottleneck.
我們有好幾個國家的 DSO 來到歷史十年低點。因此西班牙團隊做得非常出色。我們在西班牙的 DSO 是 100 天。我 2007 年去歐洲以來,已經很久沒看到 DSO 在這個水準了。DSO 改善工作的重點其實是:我們不希望 Baxter 團隊在收款流程中造成阻礙,對吧?我們不希望成為瓶頸。
I think our teams in Mexico, Italy, Spain, across the board just did a fabulous job in that regard. From a days payable standpoint, we improved one day year-over-year. This is a program that I previously referenced that we had not really seen such dividends earlier on this year because we had started it this year. But, again, one day, we have more to do in 2017. Great performance there.
我認為我們在墨西哥、義大利、西班牙的團隊,以及整體而言,在這方面都做得非常出色。從應付帳款天數的角度來看,我們年對年改善了1天。這是一項我先前提到的計畫;由於我們是今年才啟動,因此在今年較早時並未真正看到如此的成效。但再次強調,雖然只改善了1天,2017年我們還有更多工作要做。那裡的表現非常好。
Then another one -- you'll see this when we see the balance sheet. On the face of the balance sheet, inventory comes down more than $100 million as days inventory on hand declines 10 days, a remarkable performance by our supply chain team, really solid work there. So on all three dimensions of working capital, we had outstanding efforts. From a CapEx standpoint, CapEx came in a little bit lower. But if you notice our guidance, we actually guided to slightly higher CapEx next year versus this year.
接著還有另一項——當我們看到資產負債表時你們會看到。在資產負債表表面上,存貨下降超過1億美元,因為在手存貨天數下降了10天;這是我們供應鏈團隊非常亮眼的表現,工作非常扎實。因此在營運資金的三個面向上,我們都有卓越的努力成果。從資本支出(CapEx)的角度來看,CapEx略低一些。但如果你注意我們的指引,我們其實指引明年CapEx會略高於今年。
There were a couple of programs that had slight delays, nothing material, but shipping spending from December to January of Q1 along with placement of some product, again, no material impact to revenue growth or anything like that, but we did see some shift from 2016 to 2017 very modest. So I would say that CapEx, the benefits that we saw came earlier in the year, and this was a little bit more about timing. Then from a working capital standpoint, those were benefits that frankly I was banking on in 2017 that we were able to materialize earlier on.
有幾個計畫出現些微延遲,沒有任何重大影響,但把支出從12月延後到1月(第一季),並搭配部分產品的投放;同樣地,對營收成長或任何事項都沒有重大影響,但我們確實看到從2016年到2017年有非常小幅的移轉。所以我會說,CapEx方面,我們看到的效益較早在年初就已出現,而這次更多是時點問題。至於營運資金方面,坦白說那些是我原本預期在2017年才會出現的效益,但我們更早就把它實現了。
As we look to 2017, we're seeing 10% cash flow growth. We'll see continued improvement in days inventory, days sales, days payable. We will also have embedded in our numbers roughly $150 million in restructuring payments, restructuring outflows that take place in 2017. So there are some headwinds that we're facing. But we feel very confident in the $1 billion. We look forward to working hard to achieve that number. For us, I think this has been a real area of focus.
展望2017年,我們看到現金流成長10%。我們將持續改善在手存貨天數、應收帳款天數、應付帳款天數。我們的數字中也會包含約1.5億美元的重整付款,也就是2017年發生的重整現金流出。因此我們面臨一些逆風。但我們對達成10億美元非常有信心。我們期待努力工作以達成該數字。對我們而言,我認為這一直是非常重要的聚焦領域。
Because as we've thought about the valuation of our Company internally, really free cash flow conversion from sales, free cash flow conversion from EBITDA, that's a very important metric. We've strived hard to improve that, so it's nice to see that improvement in 2016. We did, by the way, with the over achievement of the $650 million by $250 million, we really did self fund the share buyback in 2016. So with that, I'll turn it over to Joe to talk about how we're going to use the cash.
因為當我們在內部思考公司估值時,自由現金流相對於銷售的轉換率、自由現金流相對於EBITDA的轉換率,都是非常重要的指標。我們一直努力改善這些,因此很高興看到2016年的改善。順帶一提,因為我們超額達成6.5億美元、超出2.5億美元,我們在2016年確實是以自有資金支應了股票回購。因此,接下來我把時間交給Joe,談談我們將如何運用這些現金。
- Chairman & CEO
- Chairman & CEO
I think the great use of cash is to provide opportunities for the Company to deliver top-quartile shareholder -- total shareholder return. So for us, it's not a matter of one versus the other, it's we can do them all. We can allocate capital to dividends. Our long-term objective is 35%, we're going to continue to pursue that. We will buy shares back opportunistically, because we're not going to horde cash in our balance sheet.
我認為現金最好的用途,是為公司提供機會,以交付同業前四分位的股東——總股東報酬。所以對我們而言,這不是二選一的問題,而是我們可以全部都做。我們可以把資本配置到股利。我們的長期目標是35%,我們會持續追求。我們也會在適當時機機會性地回購股票,因為我們不會把現金囤在資產負債表上。
But more importantly, with this cash flow performance associated with a clean balance sheet and a very, very low net debt over EBITDA, we can now contemplate inorganic opportunities that we probably were a little shy in looking into the past. So as I said in a previous meeting this year, 15% to 20% of our market cap is reasonable to think about acquisitions at that level. We have several opportunities that we're evaluating. The transformation of our portfolio in the higher weighted average growth market rate business is our objective.
但更重要的是,憑藉這樣的現金流表現,加上乾淨的資產負債表以及非常、非常低的淨負債對EBITDA比率,我們現在可以考慮一些外生成長的機會,而過去我們在評估時可能會比較保守。因此如同我今年在先前的一次會議中所說,以市值的15%到20%來思考該規模的收購是合理的。我們正在評估數個機會。我們的目標是把投資組合轉型到加權平均成長率更高的市場成長型業務。
- Analyst
- Analyst
Thanks, guys.
謝謝,各位。
- CFO
- CFO
Thank you, Vijay.
謝謝你,Vijay。
Operator
Operator
Brooks West, Piper Jaffray.
Brooks West,Piper Jaffray。
- Analyst
- Analyst
I've got two franchise level questions. First on the IV business, can you comment on where Baxter is with the upgrade cycle for Sigma Spectrum? I know there's been some competitive disruption there, so I'm wondering if there's more share to be had in the actual pump market. Then secondly, it sounded like you have a little pricing leverage within that business. Wondering if you could just talk about some of the pricing dynamics within the injectables.
我有兩個事業線層級的問題。第一個關於IV業務,你能否評論一下Baxter在Sigma Spectrum升級週期方面的進展?我知道那裡出現了一些競爭面的擾動,所以我想了解在實際的幫浦市場是否還有更多市占可爭取。第二個,聽起來你們在該業務中有一些定價槓桿。想請你談談注射劑業務中的一些定價動態。
I'll go ahead and ask my second one, just on biosurgery, Joe. It sounds like you have got a new leader there. You're guiding for that business to improve. I'm just wondering is it execution, is there a product pipeline to call out? Are you looking at deals there. If you could give us some details on how that business should start to turn around. Thanks.
我也先把第二個問題問完,關於生物外科(biosurgery),Joe。聽起來你們那邊有了新的領導人。你們指引該業務將改善。我想了解這是執行面的問題,還是有產品研發管線可以特別指出?你們是否在那裡尋求交易?如果可以,請提供一些細節,說明該業務應如何開始扭轉。謝謝。
- Chairman & CEO
- Chairman & CEO
Sure. We do have several improvements to our pump portfolio coming about for the US. We just recently also signed a development partnership deal with a very reputable company outside the US that will be augmenting our outside US portfolio. If you remember, Baxter still holds a significant amount of channels outside the US under the Colleague pump. As we space Colleague pump out, we're going to come up with a new platform soon to be able to substitute that. Then that partnership is going to grow into new areas of different applications of pumps and things of this sort.
當然。我們在美國市場的幫浦產品組合即將推出數項改良。我們最近也與一家美國以外、聲譽非常好的公司簽署了開發合作夥伴協議,將用以強化我們在美國以外的產品組合。如果你還記得,Baxter在美國以外仍透過Colleague幫浦握有相當多的通路。隨著我們逐步淘汰Colleague幫浦,我們很快會推出一個新平台來取代它。接著該合作夥伴關係也將延伸到新的領域,包括不同的幫浦應用等。
So we have two efforts that I feel very confident about. One is the internal launch and connectivity improvement and programmability of our pumps. As you know, we have best-in-class 2016 pump in the market. Our SIGMA SPECTRUM is really doing well. Then now we're going to go with an international effort with another platform. So I feel quite confident in our way to approach this market. When it comes to price dynamics, we don't comment on price dynamics. I can tell you that price has been a moderate contributor to our growth. Jay spoke earlier today about 1%.
因此我們有兩項努力,我對此非常有信心。第一是內部推出的產品,以及提升我們幫浦的連線能力與可程式化能力。如你所知,我們在市場上擁有同級最佳的2016年款幫浦。我們的SIGMA SPECTRUM表現確實很好。接下來我們將以另一個平台推動國際化的努力。所以我對我們切入這個市場的方式相當有信心。至於定價動態,我們不評論定價動態。我可以告訴你,價格對我們的成長有中度的貢獻。Jay今天稍早提到過1%。
We have long-term contracts with our hospitals in the US. These contracts are solid and are being executed. Our responsibility at the moment is actually to make sure that we have plenty of supply. We're investing money in our operations in North Carolina to the tune of $100 million to make sure that we continue to provide quality products to the market. And also creating a North American network with more capacity coming out through Canada and Mexico.
我們在美國與醫院簽有長期合約。這些合約很穩固,且正在執行中。我們目前的責任其實是確保我們有充足的供應。我們正投資約1億美元在北卡羅來納州的營運上,以確保我們持續向市場提供高品質產品。同時也在建立北美供應網路,透過加拿大與墨西哥釋出更多產能。
When it comes to biosurgery, I would have to say that our execution has not been the greatest. But with Wil Boren on board, he quickly is going to be able to turn this business around. We're looking at a nice licensing agreement right now. We're renaming this unit within our Company to advanced surgery, so it's going to open opportunities for adjacencies and acquisitions in the area so you don't only have our drug therapy but now you're going into specialty areas of surgery, which I find very refreshing.
至於生物外科,我必須說我們的執行表現並不是最好。但Wil Boren加入後,他將能很快扭轉這項業務。我們目前正在洽談一項不錯的授權協議。我們會把公司內這個單位重新命名為「先進外科」(advanced surgery),因此將在該領域開啟鄰近領域與併購的機會,讓你不僅有我們的藥物治療,現在也會進入外科的專科領域,我覺得這非常令人耳目一新。
So it's all about execution with the new person in place. We segregate this business on a global basis, a truly vertical business across Baxter. We're moving from the traditional international organization. Lastly is augmentation of licensing deals and governing of research and development. So we have a lot of faith in Wil. I'm sure he'll be able to turn this business around.
所以,隨著新的人選到位,一切都取決於執行力。我們以全球為基礎來區隔這項業務,這是 Baxter 內部真正垂直整合的業務。我們正從傳統的國際組織架構轉型。最後是擴大授權交易,以及加強研發的治理。所以我們對 Wil 非常有信心。我相信他能夠讓這項業務扭轉局面。
- Analyst
- Analyst
Great. Thanks, Joe. I appreciate the comments.
很好。謝謝你,Joe。我很感謝這些評論。
Operator
Operator
David Lewis, Morgan Stanley.
David Lewis,摩根士丹利。
- Analyst
- Analyst
Just a couple of financial questions for Jay and then one strategic one for Joe. Jay, just real quickly, a couple things, IPS performance was a little lower in the fourth quarter. That relative to our model looks a little lower in 2017 as well. So, on an underlying basis, is there something in IPS that happened in the fourth quarter that bleeds into 2017. Then operationally for the guidance for the year just the pacing of quarters. First quarter starts out very strong and then obviously that slows a little bit across the next two quarters. Is there anything going on there other than just comparables? Obviously, your second and third quarter were the toughest comps of the year. Then a quick follow-up for Joe.
先給 Jay 兩個財務問題,然後給 Joe 一個策略問題。Jay,很快問兩點:IPS 在第四季的表現稍微低一些。相較於我們的模型,2017 年看起來也略低。所以,就基本面而言,IPS 在第四季是否發生了什麼,會延續影響到 2017 年?另外,就全年指引的營運面來看,各季度的節奏安排。第一季開局非常強,然後接下來兩季顯然會放緩一些。除了基期比較之外,是否還有其他因素?顯然第二季和第三季是全年最艱難的比較基期。接著我還有一個給 Joe 的快速追問。
- CFO
- CFO
Okay. Let me hit the second one first. We do see some of the strongest growth in our Fluid Systems occurs in the first half of the year. As you'll recall, we signed a number of agreements and the last of which was really signed, I believe in the second quarter of last year. So we started to annualize those benefits in the second half, thus the slight deceleration in sales growth from really the first quarter and maybe second quarter to the rest of the year. So, that's really the seasonality factor.
好的。我先回答第二個問題。我們確實看到 Fluid Systems 的最強勁成長出現在上半年。如你所記得,我們簽了多項協議,而最後一項我相信是在去年第二季才真正簽署。因此我們在下半年開始把這些效益年化,於是從第一季、也許第二季到全年其餘時間,銷售成長率會略為減速。所以,這主要是季節性因素。
As we think about IPS, I would point out that in the US in the hospital business, we don't really do a lot of discussion around selling days. But we did have a couple of days left from a selling day standpoint, which is, call it, 3% or 4% of impact. In particular in businesses like IPS, it can have a material impact on the growth rate. So, I would point to that. I think there's not really other trends going on in that particular business. We continue to be very excited about it. IPS, as you know, includes nutrition, GPI, our injectables business, which so far, the injectables, we're very optimistic about that space.
談到 IPS,我想指出,在美國的醫院業務中,我們通常不太會花很多時間討論銷售天數。但從銷售天數的角度來看,我們確實少了幾天,影響大約可說是 3% 或 4%。特別是在像 IPS 這樣的業務中,這可能會對成長率造成實質影響。所以我會把原因指向這點。我認為該業務並沒有其他特別的趨勢在發生。我們仍然對它感到非常振奮。如你所知,IPS 包含營養、GPI,以及我們的注射劑業務;就注射劑而言,到目前為止我們對這個領域非常樂觀。
- Analyst
- Analyst
Okay. Then, Joe, just if I go back to the analyst day and think about strategic priorities, you have this 40% of the Company is dialysis. You have a product suite there that's delivering and obviously good guidance for 2017. You spelled out the importance of generic injectables and getting that platform for Brook's group and that happened. Now, with Wil being on board and renaming that group, is the one area where there's the greatest opportunity to transform the growth rate of the Company, is that really in this advanced surgery, biosurgery space? That seems to be the one hole post the Analyst Day that could be filled with strategic action. Thank you.
好的。那麼,Joe,如果我回到分析師日並思考策略優先事項,你們公司有 40% 是透析業務。你們在那裡有一套產品組合在交付成果,且顯然對 2017 年給出了不錯的指引。你也闡述了學名注射劑的重要性,以及為 Brook 的團隊建立那個平台,而那也已經發生了。現在 Wil 加入並為該團隊重新命名後,公司最有機會改變成長率的領域,是否真的在這個先進外科、BioSurgery 的領域?在分析師日之後,這似乎是唯一一個可以透過策略行動來補上的缺口。謝謝。
- Chairman & CEO
- Chairman & CEO
David, that points to a great area of opportunity. I think inorganic -- in organically and now with our balance sheet and our performance in cash flow, I feel more confident in how we go about these businesses because it gives us more flexibility. I think when you start going away from classifying your business as products or narrow areas, it opens a strategic opportunity (inaudible) So in the surgery business, I think that is the case.
David,你指出了一個很好的機會領域。我認為在外延式成長(併購)——以及內生成長方面——現在憑藉我們的資產負債表與現金流表現,我對我們推進這些業務的方式更有信心,因為這讓我們更有彈性。我認為當你開始不再把業務分類為產品或狹窄的領域時,就會打開策略機會(聽不清)。
I would like to underscore that renal despite the fact that we're market leaders in peritoneal dialysis and we have been gaining market share in the US and other markets in acute renal care, which is our CRRT versus our competition because our technology is far superior. I would say that there is still opportunity in peritoneal dialysis for growth in emerging markets with technology that currently does not exist there.
我想強調,腎臟業務方面,儘管我們在腹膜透析是市場領導者,而且在美國及其他市場的急性腎臟照護(也就是我們的 CRRT)相較競爭對手持續提升市占,因為我們的技術明顯更優。我會說,腹膜透析在新興市場仍有成長機會,因為那裡目前還沒有現有的相關技術。
So I feel that we always are going to have that nice business, 5%, 6% growth in renal that keeps churning and churning and delivering on cash. Giuseppe Accogli has done a great job with his team turning the [in-stent] hemodialysis business around and with the adoption of AMIA with the [in stellar medical platform]. I feel really confident about that business. So as we see new opportunities in adjacencies, I still think that our base renal business continues to churn a great deal of cash in helping the Company finance expenditure in that area and other areas.
因此我認為,我們的腎臟業務將一直是一門很好的生意,以 5%、6% 的成長持續運轉並帶來現金。Giuseppe Accogli 與他的團隊在扭轉 [in-stent] 血液透析業務方面做得非常出色,並且隨著 AMIA 在 [in stellar medical platform] 上的採用而改善。我對那項業務非常有信心。所以當我們在相鄰領域看到新機會時,我仍然認為我們的核心腎臟業務會持續產生大量現金,協助公司為該領域以及其他領域的投入提供資金。
Operator
Operator
Larry Biegelsen, Wells Fargo.
Larry Biegelsen,富國銀行。
- Analyst
- Analyst
So, Joe, emerging markets are about 25% of Baxter sales. Can you talk about what you're seeing for Baxter in emerging markets? What was growth in Q4? What's your expectation for 2017? I had one follow-up. Thanks.
Joe,新興市場約占 Baxter 銷售的 25%。你能談談你在新興市場看到 Baxter 的情況嗎?第四季的成長是多少?你對 2017 年的預期是什麼?我還有一個追問。謝謝。
- Chairman & CEO
- Chairman & CEO
Our emerging markets totaled 3% growth in the fourth quarter. But I would like to qualify that all of our exits are happening in that market. We're exiting some of the business in India, Turkey and Venezuela. They're depressed. I would like to point out that in Greater China, we're up now to 6% with plans to get to high single-digit growth. We see our peritoneal dialysis business recovering in China, which is very important to us.
我們的新興市場在第四季合計成長 3%。但我想補充說明,我們所有的退出動作都發生在該市場。我們正在退出印度、土耳其和委內瑞拉的部分業務。這些市場表現低迷。我想指出,在大中華區,我們目前成長已達 6%,並計畫提升到高個位數成長。我們看到腹膜透析業務在中國正在復甦,這對我們非常重要。
We also see recovery in Latin America. Some of the underlying growth here will be primarily biosurgery and peritoneal dialysis, areas we're going to focus. As you know, we are exiting or going to be exiting a lot of the IP businesses, some of the markets that we're not making any money, the other way we're losing money. So I feel that we have now an investment plan for China, which will bring that business close to $1 billion in a few years.
我們也看到拉丁美洲正在復甦。這裡的部分基本面成長主要將來自 BioSurgery 和腹膜透析,這些是我們將聚焦的領域。如你所知,我們正在退出或將退出許多 IP 業務,以及一些我們不賺錢、甚至在虧錢的市場。因此我認為,我們現在已經有一個針對中國的投資計畫,將在幾年內把那裡的業務帶到接近 10 億美元。
We are very, very bullish about Latin America and our extended investment there. So I would say that for the mid-term to long-term on growth rates we're looking at low -- high single-digits for that region. So once we get over this comp 12 months of us exiting the business in India, China -- I'm sorry, India, Turkey and Venezuela.
我們對拉丁美洲以及在當地擴大投資非常、非常看多。所以我會說,就中期到長期的成長率而言,我們預期該地區將達到低——高個位數。也就是說,一旦我們度過這 12 個月的比較期(我們正在退出印度、土耳其和委內瑞拉的業務;中國——抱歉,是印度、土耳其和委內瑞拉)。
- Analyst
- Analyst
Thank you. That's very helpful. Just back to Claris. I know there was a question asked on that earlier, but can you tell us what the sales were for 2016 and the growth? I'm asking because the IMS data implies for at least the US at growth was north of 50% through the first three quarters of 2016. I wanted to confirm that if it closes later this year, it's about a $0.01 to $0.02 benefit in 2017. Thanks for taking the questions.
謝謝。這非常有幫助。再回到 Claris。我知道先前有人問過,但你能告訴我們 2016 年的銷售額以及成長率嗎?我之所以問,是因為 IMS 數據顯示,至少在美國,2016 年前三季的成長率超過 50%。我想確認一下,如果今年稍晚完成交割,2017 年大約會帶來 0.01 到 0.02 美元的效益。謝謝回答問題。
- Chairman & CEO
- Chairman & CEO
So we are planning to close Claris as fast as we can. But the realistic approach is probably the second half, July, August. We'll give more clarity. We're talking about a couple cents a share for this year. The Company has north of $100 million in sales. So you can do some of the math. I would think we will come out with a very transparent guidance on how is that going to affect 2018. You can put in your long range plan what that will do for us. We'll keep you guys posted on the acceleration programs that we're put into place for additional molecules for this market.
因此,我們計劃以最快速度關閉 Claris。但較為務實的做法可能是在下半年,也就是 7 月、8 月。我們會提供更明確的說明。就今年而言,我們談的是每股影響約幾美分。公司銷售額超過 1 億美元。所以你可以自己算一算。我認為我們會提出非常透明的指引,說明這將如何影響 2018 年。你可以把這對我們的影響納入你的長期規劃。我們也會持續向各位更新我們為這個市場推動的加速計畫,以導入更多分子。
- Analyst
- Analyst
Thank for taking the questions.
謝謝讓我提問。
- CFO
- CFO
Thank you, Larry.
謝謝你,Larry。
Operator
Operator
Bob Hopkins, Bank of America.
美國銀行的 Bob Hopkins。
- Analyst
- Analyst
Just a quick question first for you, Jay, on the guidance. I know we talked about this a little bit already in terms of how Q1 starts and then the rest of the year. But what I'm curious about, if you could just talk about, what drives the improving underlying growth in Q1 versus Q4? Because I think in Q4 you said you grew 3% and then you're expecting 5% to 6% underlying in Q1. Is that just comps or what drives such an acceleration from Q4 to Q1?
我先問一個簡短的問題,Jay,關於指引。我知道我們先前已稍微談過,關於第一季的開局以及今年其餘時間的情況。但我好奇的是,你能否談談,是什麼驅動第一季相較第四季基礎成長的改善?因為我記得你說第四季成長 3%,而你預期第一季基礎成長為 5% 到 6%。這只是比較基期(comps)的因素,還是是什麼驅動第四季到第一季如此加速?
- CFO
- CFO
Yes, it's interesting. There's definitely a comp factor in play. As we look back to last year, we had a strong Q4 and then Q1 was not quite as relatively strong as Q4. But then -- and I don't want to get into this whole billing day thing, but it is a factor that comes into play in particular in our hospital business globally. We lost a couple of billing days which was several points of growth. I believe in Q1 we actually gained one billing day. So that swing factor actually modulates the growth rate to some extent. Those are really the factors that are in play.
是的,這很有意思。確實有比較基期因素在起作用。回頭看去年,我們第四季很強,而第一季相對於第四季並沒有那麼強。不過——我不想深入談整個「開帳日」這件事,但它確實是一個因素,特別是在我們全球的醫院業務中。我們少了幾個開帳日,這對成長率影響了好幾個百分點。我相信在第一季我們實際上多了一個開帳日。因此,這個擺動因素在某種程度上確實會調節成長率。這些就是正在起作用的因素。
- Analyst
- Analyst
Okay. So it's less fundamental issues, more calendar issues it sounds like just in terms of Q4 to Q1.
好的。所以聽起來,從第四季到第一季,與其說是基本面問題,不如說是行事曆因素。
- CFO
- CFO
Exactly.
沒錯。
- Analyst
- Analyst
Then Joe for you, again, for everybody, congrats on a great 2016. You've talked a lot about M&A already on this call. But I was wondering if you could just in broad terms set expectations for us for M&A in 2017? How likely are deals? How confident are you that there are attractive assets out there that could be priced at levels that you find interesting in 2017?
接著 Joe,先恭喜各位 2016 年表現很出色。你們在這通電話中已經談了很多併購(M&A)。但我想請你從較宏觀的角度,為我們設定一下 2017 年併購的預期?交易發生的可能性有多大?你對於 2017 年市場上存在具吸引力、且價格在你們覺得有意思的水準的資產,有多大信心?
- Chairman & CEO
- Chairman & CEO
Bob, it is quite a task to answer your question, because it's opportunistic and our efforts are relentless. So eventually we're going to get to the right target. We're working very hard. As you know, we've rebuilt our M&A team completely from scratch. We have very good people on board.
Bob,要回答你的問題其實相當不容易,因為這是機會導向,而我們的努力是不間斷的。所以最終我們會找到合適的標的。我們正在非常努力地推進。如你所知,我們已從零開始徹底重建了我們的併購團隊。我們有非常優秀的人才加入。
But we are financially disciplined. So our ability to strategically identify targets is there. But things have to work. Some assets are expensive. We want to make sure that we can extract value because our first priority is to really return to the top quartile in total shareholder returns. We'll do that. We have plenty of targets, a good team in place, good direction where to go.
但我們在財務上很自律。因此,我們具備策略性辨識標的的能力。但各項條件必須到位。有些資產很昂貴。我們要確保能夠提取價值,因為我們的首要任務是讓總股東報酬回到同業前四分位。我們會做到的。我們有很多標的、也有一支很好的團隊到位,方向也很清楚。
We need to find the opportunity where this target becomes available or is interested and the price is something that will be attractive to the Company. No, we are always speaking about three to five years Company average ROIC return. We're talking about internal rate of return greater by far exceeding cost of capital, all debt and equity included. So we will continue down this path. But we are excited about the position that we have in our balance sheet. But that does not create a bias for us to act without thinking about the financial returns.
我們需要找到一個機會:這個標的可取得或有意願交易,而且價格對公司而言具有吸引力。我們一直談的是公司三到五年的平均 ROIC 回報。我們談的是內部報酬率(IRR)要遠高於資本成本,包含所有負債與股權在內。所以我們會持續沿著這條路走下去。我們對資產負債表上的位置感到振奮。但這不會讓我們產生偏誤,去做出未經深思、而不考量財務報酬的行動。
- Analyst
- Analyst
Great. Thanks for taking the questions.
很好。謝謝讓我提問。
Operator
Operator
Matt Miksic, UBS.
瑞銀的 Matt Miksic。
- Analyst
- Analyst
So I just wanted to -- I know there's been a couple of questions on Claris and on some of the other efforts that you're making across the portfolio to improve performance. We thought the Claris deal was right on target with the injectable strategy layout last year. But one of the things, it's come up a couple times in the call, is that we think you're doing particularly well and would love to hear some thoughts on 2017 is, the impact of product line rationalization particularly by geography.
我想問的是——我知道已經有幾個問題談到 Claris,以及你們在整個產品組合中為提升績效所做的一些其他努力。我們原本認為 Claris 交易與去年提出的注射劑策略布局非常吻合。但有一件事在這通電話中被提到好幾次,我們認為你們做得特別好、也很想聽聽你們對 2017 年的看法:也就是產品線精簡(rationalization)的影響,特別是按地理區域來看。
You mentioned some of the changes here in the back half. I was wondering, Jay, if you could talk a little bit about the size or the scale of that contribution to your underlying 300 basis point operating improvement you talked about before headwinds. I have one follow-up.
你提到下半年的一些變化。Jay,我想請你談談,這項貢獻在你先前提到、在逆風之前的 300 個基點營運改善中,大概占多大或多大規模?我還有一個追問。
- CFO
- CFO
Yes, it's interesting because for us over the last 1.5 years -- we really intensified the focus over the last six months and we've been focused on rationalizing the portfolio and challenging every single sale. I think we've done a nice job looking at the fully loaded and variable profitability of every product line in every country in which we operate.
是的,這很有意思,因為過去 1.5 年我們——在過去六個月其實大幅強化了焦點——一直專注於精簡產品組合,並挑戰每一筆銷售是否合理。我認為我們做得不錯,檢視了我們營運所在每個國家、每條產品線的完全成本(fully loaded)與變動獲利能力。
As part of that, we identified a set of sales which didn't quite make sense for us on a going-forward basis. So we walked away and the impact next year is around $100 million in sales. That was really a zero margin contribution. So the simple fact of walking away from those sales is roughly 10 to 20 points of margin improvement due to those strategic exits.
在這個過程中,我們辨識出一組從長遠來看對我們而言不太合理的銷售。因此我們選擇退出,而明年的影響約為 1 億美元的銷售額。那基本上是零毛利貢獻。所以,單純退出這些銷售,因為這些策略性退出,約可帶來 10 到 20 個基點的毛利率改善。
Now, it's important to note as we sit here today, I think we have cleansed the portfolio to the extent that it needs to be cleansed at this stage. Of course, things change. So it could be a foreign currency evolution. It could be pricing pressure in a particular emerging market, which would cause us to relook at this.
另外要強調的是,以我們今天的狀態來看,我認為我們已在現階段把產品組合清理到需要的程度。當然,情況會改變。可能是外匯走勢的變化。也可能是某個新興市場的定價壓力,促使我們重新檢視這件事。
But, again, as we sit here today, I think we feel very confident that all of the sales that we have contribute positively to the economics of Baxter. But now it's about, from a portfolio management standpoint, not so much walking away but shifting our R&D investments and SG&A investments towards those areas that we think our promotionally sensitive, where Baxter has a proprietary right to win, where we have higher margin. That will be the next leg of the journey as we think about margin improvement related to portfolio management.
但同樣地,以我們今天的狀態來看,我們非常有信心,我們所有的銷售都對 Baxter 的經濟效益有正向貢獻。但接下來,從產品組合管理的角度,重點不再是退出,而是把我們的研發投資與銷售、一般及行政(SG&A)投資,轉向我們認為對推廣更敏感、Baxter 具備專有優勢能夠勝出的領域,以及毛利更高的領域。當我們思考與產品組合管理相關的毛利率改善時,這將是旅程的下一個階段。
- Analyst
- Analyst
That's great. The follow-up, again, this is a theme that's come up in a couple of other questions on pricing. But just given the sensitivity and the focus on this, particularly drug pricing which is away from your core lines of business, it would be helpful to understand -- I think we understand that the vast majority of growth is driven by volumes. But we often think in terms of things like price, net of mix or price and mix as the other variables plus or minus around that growth rate. Are you living in sort of a negative price world with some positive mix? Or the other way around? Or how should we think about it?
這很棒。追問一下,這也是在其他幾個關於定價的問題中出現的主題。但考量到這件事的敏感度與關注度,特別是藥品定價(這其實偏離你們的核心業務線),若能理解會很有幫助——我想我們理解絕大多數成長是由量(volumes)所驅動。但我們常會用「價格(price)扣除組合(mix)」或「價格與組合(price and mix)」作為其他變數,來解釋成長率周邊的正負影響。你們目前是處在一個價格為負、但組合為正的世界嗎?還是相反?或者我們應該如何看待這件事?
- CFO
- CFO
Yes. Look, I think, what I would say is as we look at 2017, to be clear, we have roughly 30 basis points of pricing in our numbers. So it's not a substantial number from an overall pricing standpoint. Really that's not new price increases that we're anticipating in so much as it is previously agreed to agreements that we have in place with our major customers with kind of normal price increases attached to them. So really that's the environment that we're operating in.
是的。你看,我想我會說的是,當我們看2017年時,講清楚一點,我們在數字裡大約納入了30個基點的定價。所以從整體定價角度來看,這不是一個很大的數字。實際上,這並不是我們所預期的新一輪漲價,而更多是我們與主要客戶既有、先前已談妥的協議,這些協議通常會附帶正常的價格上調。所以,這就是我們所處、所運作的環境。
As we've said, when we look at our long range plan, we see a fairly neutral price environment. There's some benefit and some areas where we're seeing pressure. We've commented historically about price pressure in the area of dialysers, but we've also commented about things like the launch of AMIA and what that does as a new therapy and ability to charge a higher price because of the great value that we're providing with that product. So, it's a difficult question to answer. But what I can say is, we're not really counting on much price. We think the environment is fairly neutral. It's a little bit different than some of the other dynamics that are in play with other areas in healthcare.
正如我們所說,當我們看我們的長期計畫時,我們看到的是一個相當中性的價格環境。有些方面有利,也有些領域我們看到壓力。我們過去曾評論過在透析器領域的價格壓力,但我們也談到像AMIA的上市,以及作為一種新療法,它所帶來的影響——由於我們用該產品提供了很高的價值,因此能夠收取較高的價格。所以,這是一個很難回答的問題。但我能說的是,我們其實並沒有太多把價格因素算進去。我們認為環境相當中性。這與醫療保健其他一些領域正在發生的動態有些不同。
- Analyst
- Analyst
Thanks so much.
非常感謝。
Operator
Operator
Glenn Novarro, RBC Capital Markets.
RBC資本市場的Glenn Novarro。
- Analyst
- Analyst
First, Jay, did you give us targets for gross margin and R&D ratio for 2017?
首先,Jay,你有給我們2017年的毛利率與研發費用比率目標嗎?
- CFO
- CFO
We did not share those targets. I think from a gross standpoint, we're looking at roughly 50 basis points of expansion next year. Mind you, some of the foreign-exchange impact and some of the cyclo impact in particular impact that line, which is why we're not seeing more expansion. From an R&D standpoint, we're looking at mid single-digit increase.
我們沒有分享那些目標。我想就毛利率而言,我們預期明年大約擴張50個基點。請注意,部分外匯影響,尤其是cyclo的影響,會影響那一條線,這也是為什麼我們看不到更大的擴張。就研發而言,我們預期是中個位數的成長。
It's interesting because our R&D team has done a very nice job looking at infrastructure cost and controlling cost and diverting spending to new product development. So while we're only increasing mid single-digit, the actual amount spent on project is going up fairly substantially. So we're pleased with that. Then from an SG&A standpoint, we expect, again, there will be a decline in SG&A down low to mid single-digits. That's in large part driven by the zero base budgeting techniques that we're applying across the portfolio.
這很有意思,因為我們的研發團隊在檢視基礎設施成本、控制成本,並把支出轉向新產品開發方面做得非常好。所以雖然我們只增加中個位數,但實際投入到專案上的金額相當大幅提升。因此我們對此感到滿意。另外在SG&A方面,我們預期同樣會下降,降幅約為低到中個位數。這在很大程度上是由於我們在整個產品組合中採用零基預算(zero base budgeting)技術所驅動。
- Analyst
- Analyst
Okay. Then let me just follow-up on that SG&A comment, just because one of the questions that I often get from investors is how sustainable or how much runway is left in terms of bringing down SG&A? In other words, has all of the low hanging fruit been removed? So maybe some thoughts either from Joe or Jay in terms of the sustainability of the SG&A decline over time? Thanks.
好的。那我就針對你剛才的SG&A評論追問一下,因為投資人常問我的一個問題是:在降低SG&A方面,這有多可持續、或還剩下多少空間?換句話說,所有唾手可得的成果是否都已經拿到了?所以也許Joe或Jay可以談談,SG&A隨時間下降的可持續性?謝謝。
- Chairman & CEO
- Chairman & CEO
Glenn, we are in the middle of doing it. We still have a few programs that are in process of being contemplated. What I'm finding here at Baxter that I did not find before in my previous experience is that the business transformation office has changed the way we look at things and how we spend money and the effectiveness of our spending pattern. So we are now a Company that is, for the vast majority, a six-layer Company with very few exceptions.
Glenn,我們正在進行當中。我們仍有幾個方案正在評估與規劃中。我在Baxter這裡發現一點,是我在先前經驗中沒有看到的:業務轉型辦公室改變了我們看事情的方式、花錢的方式,以及我們支出模式的有效性。因此,我們現在這家公司在絕大多數情況下是一家六層級的公司,只有極少數例外。
We're a Company that understands category management. But every meeting that we go, we go to a two-hour business transformation meeting every month. We just identified a significant amount of savings in the future of programs we're not contemplating. So this is a journey, this not a project. So do we have more? Yes. Is there more elasticity? Yes.
我們是一家理解品類管理(category management)的公司。而且我們每個月都會參加一次兩小時的業務轉型會議。我們剛剛在未來、在一些我們尚未納入考量的方案中,識別出相當可觀的節省空間。所以這是一段旅程,不是一個專案。所以我們還有更多嗎?有。還有更多彈性嗎?有。
Do we want to see the SG&A lower? Yes. What is the right SG&A for this Company? Well, we're going to talk more about what we think the margins are going to be in 2020 later this year. So then you can estimate what the SG&A is going to be as a target. But we're not satisfied. We're happy with the progress and the people of Baxter has done a great job embracing this very difficult way of managing business in terms of expense.
我們希望SG&A更低嗎?是的。這家公司合理的SG&A水準是多少?嗯,我們會在今年稍晚更多談談我們認為2020年的利潤率會是多少。那麼你就可以推估SG&A的目標水準。但我們並不滿足。我們對進展感到高興,而Baxter的員工在以費用角度採用這種非常困難的企業管理方式上,做得非常好並且積極擁抱。
- Analyst
- Analyst
Okay. Great. Thanks, Joe.
好的。很好。謝謝你,Joe。
- Chairman & CEO
- Chairman & CEO
You're welcome.
不客氣。
Operator
Operator
Joanne Wuensch, BMO Capital Markets.
BMO資本市場的Joanne Wuensch。
- Analyst
- Analyst
Very nice quarter. Joe, you've been there for about a year now. What would you say were your key highlights to take-aways? A year from now when we're all together, what do you really want to make sure that we have seen happen this year?
這一季表現非常好。Joe,你到任大約一年了。你會說你的關鍵亮點或主要收穫是什麼?一年後當我們再聚在一起時,你最希望確保我們今年已經看到哪些事情發生?
- Chairman & CEO
- Chairman & CEO
Joanne, I was surprised by a culture that was ready to be changed. People here were looking for a change. So some of the things that we were doing in terms of portfolio management, reallocation of R&D resources, completely revamping of our marketing organizations, how we organize our BD&L, our M&A groups. This has been a significant change in how people used to do business. Folks here have adopted and really didn't used to be in getting on with the program.
Joanne,我對一種已準備好改變的文化感到驚訝。這裡的人一直在尋求改變。因此,我們在產品組合管理、研發資源重新配置、徹底改造行銷組織、我們如何組織BD&L以及我們的併購(M&A)團隊等方面所做的一些事情,對於人們過去的做事方式而言,是非常重大的改變。這在大家過去的業務運作方式上帶來了顯著變化。這裡的同仁已經採納並真正投入,而不是像以前那樣不太跟上計畫。
So I will highlight that of everything we're doing, we couldn't have done it without the great employees of Baxter. On looking forward, if I'm standing here a year from today, what I would like to see. I would like to see this biosurgery business start to transform itself and look for opportunities outside. I would like to see us with probably another 100 to 200 molecules in our pipeline above what we have today.
所以我要強調的是,在我們所做的一切之中,如果沒有Baxter優秀的員工,我們不可能做到。展望未來,如果我在一年後的今天站在這裡,我希望看到的是:我希望這個生物外科(biosurgery)業務開始自我轉型,並尋找外部機會。我希望看到這個生物外科業務開始轉型,並尋找外部機會。我也希望我們的研發管線中,分子數量能比今天再多大約100到200個。
I would like to see us with a well defined pump technology, which is not only US but is a global one that has the ability to be in the three levels of pump platforms that we need to have. So I have a significant expectations. Lastly is to make sure that we don't lose the sense of urgency and the speed by which we transform the Company.
我希望我們能擁有一個定義清晰的幫浦技術,不僅適用於美國,也是一個全球性的技術,並且能夠涵蓋我們所需要的三個層級的幫浦平台。所以我有相當高的期待。最後是要確保我們不會失去緊迫感,以及我們推動公司轉型的速度。
- Analyst
- Analyst
As my follow-up, there's been a lot of questions already on M&A. We throw around a lot of different names amongst ourselves. But what is your current thinking about adding another leg to the stool? Or is it really just adding in things to your current structure? Thank you.
作為我的追問,關於併購(M&A)已經有很多問題了。我們彼此之間會提到很多不同的名字。但你目前對於「再加一條腿」的想法是什麼?還是其實只是把一些項目加到你現有的架構裡?謝謝。
- Chairman & CEO
- Chairman & CEO
We will continue to look at adjacencies. You have got to be able to walk before we go into the triathlon here. So a white space and a brand new leg on the stool becomes a high order for a Company that has not done many M&As and in the areas that they did were always on adjacencies. So we did not look into adjacencies, we have not looked in the past. However, to have a complete new leg of the stool, I think, is a little premature for us to speak about.
我們會持續尋找相鄰領域(adjacencies)。在我們去參加鐵人三項之前,你得先學會走路。因此,對一家過去沒有做過很多併購、而且即便做也多是在相鄰領域的公司而言,所謂的「白地」以及在凳子上新增一條全新的腿,會是一個非常高階的要求。所以我們沒有去看那些過去未曾涉足的相鄰領域。不過,要新增一條完全新的腿,我認為現在談這個還稍嫌過早。
- Analyst
- Analyst
Thank you.
謝謝。
Operator
Operator
Larry Keusch, Raymond James.
Raymond James的Larry Keusch。
- Analyst
- Analyst
So, Joe, for the year on a constant currency basis, it looks like you did 6% growth in the US and about 3% overseas. So I wanted to just pick your brain a little bit on how you think about accelerating the overseas growth. Because I think it's probably a bit below what you're anticipating in your LRP. I just wanted to see if you could expand upon that a little bit.
所以,Joe,以固定匯率基礎來看,今年你們在美國看起來成長了6%,海外約成長3%。我想稍微請教一下,你如何看待加速海外成長。因為我認為這可能比你在長期規劃(LRP)中預期的略低一些。我想看看你是否能再多談一點。
- Chairman & CEO
- Chairman & CEO
Larry, a couple of things. The overseas will be backed by two or three factors. Let me start by saying that once we anniversary, the exits of $137 million in sales that we are exiting in Turkey, India and Venezuela for the most part, you'll gain a good -- no, 1.4%, 1.5%, 150 basis points of incremental growth. Right on that. Second thing is we must improve performance in Europe. We're making some changes in Europe to make sure that we get the right people in place so we can get performance. It has been awhile.
Larry,有幾點。海外將由兩到三個因素支撐。我先說,一旦我們度過比較基期,我們在土耳其、印度與委內瑞拉等地大致退出的1.37億美元銷售額,將帶來不錯的——不,是1.4%、1.5%,也就是150個基點的額外成長。就在那一點上。第二點是我們必須改善歐洲的表現。我們正在歐洲做一些調整,確保把合適的人放到位,讓我們能夠提升績效。已經有一段時間了。
Despite the fact that Europe is a slow growth market, it's a difficult market for the most part that fell a part of Europe, not the emerging part of Europe, which would be the Eastern Europe, Middle East and Africa, which in 2017, we're expecting good growth from it. I want to make sure that we have the right structure in Europe. We're making changes to that effect. Also getting the biosurgery out of the Baxter structure on the [full] vertical organization and a couple of licensing deals, I think we can accelerate that. So our objective for outside the US is make sure that we return to a 4.5% to 5% growth rate in the midterm.
儘管歐洲是低成長市場,而且整體而言是個困難的市場——我指的是歐洲的成熟市場部分,而不是新興的歐洲部分;新興部分包括東歐、中東與非洲,我們預期2017年那裡會有不錯的成長。我想確保我們在歐洲有正確的架構。我們正朝這個方向做調整。另外,把生物外科(biosurgery)從Baxter的架構中、從[full]垂直式組織中拆出來,再加上幾個授權交易,我認為我們可以加速成長。因此,我們對美國以外市場的目標,是確保中期回到4.5%到5%的成長率。
- Analyst
- Analyst
Okay. Perfect. Then the other quick question is, just thinking about your pump business specifically, how are you thinking in the 2017 outlook relative to the potential for a pause in spending at the hospital level given some of the uncertainties around ACA?
好的。完美。那另一個快速問題是,特別就你們的幫浦業務來看,針對2017年的展望,在ACA相關不確定性下,醫院端支出可能暫停的風險,你們是怎麼看待的?
- Chairman & CEO
- Chairman & CEO
Listen, it's very uncertain right now with this whole repeal and replace. What would be actually the replacement policy? What is going to be placed to bring coverage to people that may be out of coverage? So I think hospitals always take a pause at big capital items and investment and expansion. I would say that capital plans that we have -- the capital products that we have, rather, is small capital investments that the hospital needs to make.
聽著,現在整個「廢除並取代」的議題非常不確定。實際的替代政策會是什麼?會用什麼方式來讓可能失去保險覆蓋的人重新獲得保障?所以我認為,遇到大型資本項目、投資與擴張時,醫院通常都會先暫停一下。我會說,我們所提供的資本計畫——更正,我們的資本產品——屬於醫院必須做的小型資本投資。
Those are bumps. They need the bumps. These are not big diagnostic machines. So I would say that if there is an effect and it's a cascading effect, we're probably at the tail-end of it and we'll see little of that, if any, into 2017. I would say that we have performed tremendously well with our SIGMA SPECTRUM pumps in the US in the last two years. Clearly, we're going to see that flattening out into 2017 because the number of accounts that we took from competitors.
那些是「bumps」。他們需要這些「bumps」。這些不是大型診斷設備。所以我會說,即便有影響,而且是連鎖效應,我們大概也已經在尾端了,2017年可能幾乎看不到,或頂多只有一點點。我會說,過去兩年我們的SIGMA SPECTRUM幫浦在美國表現非常出色。很明顯地,到了2017年會趨於平坦,因為我們從競爭對手那裡拿下的客戶數量。
But that is independent of the fact that the capital policy for hospitals based on the environment, the political environment and the mandates, they're coming down. So let's separate them. I think Baxter will have a good performance in 2017, maintaining its base and selectively expanding its base in hospitals with more beds in the US. Because we took a significant market share in the last two years. So now is to maintain slight growth, and make sure utilization of those pumps are done correctly.
但那與醫院在當前環境、政治環境與相關要求之下的資本政策收緊,是兩回事。所以我們把它們分開看。我認為Baxter在2017年會有良好表現:維持既有基礎,並在美國床位數較多的醫院中有選擇地擴大基礎。因為過去兩年我們拿下了顯著的市占。所以現在就是維持小幅成長,並確保這些幫浦的使用率能被正確地落實。
- Analyst
- Analyst
Okay. Perfect. Thank you very much, Joe.
好的。完美。非常感謝你,Joe。
- Chairman & CEO
- Chairman & CEO
Thank you.
謝謝。
Operator
Operator
Danielle Antalffy, Leerink Partners.
Danielle Antalffy,Leerink Partners。
- Analyst
- Analyst
Congrats on a great quarter. Jay, I was hoping you could give some color on some of the various top line headwinds as we head into 2017. Well, the headwinds and tailwinds as well. Just thinking about your underlying growth projection or guidance for 4% is below the 5% you delivered in 2016. Just looking to get some color on the puts and takes there. Thanks so much.
恭喜本季表現出色。Jay,我希望你能就我們邁入2017年時,營收端面臨的各種逆風提供一些說明。當然也包括順風。我在想,你們對內生成長的預估或指引是4%,低於你們2016年交出的5%。想請你多談談其中的增減因素。非常感謝。
- CFO
- CFO
Yes, 2016, we did benefit from a Fluid Systems performance that I would say is above the long-term steady state. In part because we have the benefit of the first quarter, really is the first early stages of the SIGMA SPECTRUM relaunch and in part because of all of the work we did in terms of volumes in contracting in our Fluid Systems business.
是的,2016年我們確實受惠於Fluid Systems的表現,我會說那高於長期穩態水準。部分原因是我們受惠於第一季——那其實是SIGMA SPECTRUM重新上市初期的早期階段;另一部分原因是我們在Fluid Systems業務上,針對合約與出貨量所做的所有工作。
So really the biggest driver of the deceleration, excluding the one-time impact relates to the slowdown -- expected slowdown, I should say, in our Fluid Systems business. As we move to 2017, I think there are just a few important points, right. We've got a cyclo impact that's about $100 million. We've got a strategic exits impact, that's about $100 million. Then the rest of the portfolio is kind of largely in line with our long-term expectations. So no radical departures. But the stabilization of the Fluid Systems business which will continue to grow a little faster in the first half of the year, that's the biggest driver of the change of growth rate.
所以,真正造成成長放緩的最大驅動因素(不含一次性影響)與我們Fluid Systems業務的放緩——我應該說是預期放緩——有關。展望2017年,我認為有幾個重點。我們有一個cyclo影響,約1億美元。我們有策略性退出的影響,約1億美元。其餘產品組合大致與我們的長期預期一致。所以沒有什麼劇烈的偏離。但Fluid Systems業務的穩定化——它在上半年仍會成長得稍快一些——是成長率變化的最大驅動因素。
- Analyst
- Analyst
Perfect. That makes total sense. Thanks for that. Then any major tenders I guess specifically in the renal business that we should be cognizant of over the next 12 months that are coming up?
完美。這完全說得通。謝謝你的說明。那接下來12個月,在腎臟業務方面,有沒有任何我們需要留意的重大標案即將到來?
- CFO
- CFO
We have nothing major at this stage from a significant tender standpoint to point out. We do have a lot of our business that goes through tenders outside of the US. Some of them are large tenders. Some of them are small tenders. But as we sit here, nothing major to point out to that would be an area of concern for us.
就目前而言,從重大標案的角度,我們沒有什麼特別需要指出的。我們在美國以外有很多業務是透過標案進行。其中有些是大型標案。有些是小型標案。但以我們現在的情況來看,沒有什麼重大事項需要特別提出、也不會是我們關切的領域。
- Analyst
- Analyst
Okay. Thank you.
好的。謝謝。
- Chairman & CEO
- Chairman & CEO
I just want to augment Jay's question quickly as we're seeing 5% to 6% increasing patients and PE which is a great indicator for us into 2017.
我想快速補充Jay的問題:我們看到病患數與PE增加5%到6%,這對我們進入2017年而言是很好的指標。
- Analyst
- Analyst
Perfect. Thank you very much.
完美。非常感謝。
- Chairman & CEO
- Chairman & CEO
Thanks, Danielle.
謝謝你,Danielle。
Operator
Operator
Thank you. There are no further questions at this time. Ladies and gentlemen, this concludes today 's conference call with Baxter International. Thank you for participating. Everyone, have a great day.
謝謝。目前沒有其他問題。各位女士、先生,今天Baxter International的電話會議到此結束。感謝各位參與。祝各位有美好的一天。